Publication: Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil
Issued Date
2002-12-15
Resource Type
ISSN
10584838
DOI
Other identifier(s)
2-s2.0-0037115248
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Infectious Diseases. Vol.35, No.12 (2002), 1498-1504
Suggested Citation
Michèle Van Vugt, Elisabetta Leonardi, Lucy Phaipun, Thra Slight, Kyaw Lay Thway, Rose McGready, Alan Brockman, Leopoldo Villegas, Sornchai Looareesuwan, Nicholas J. White, Franc̃ois Nosten Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. Clinical Infectious Diseases. Vol.35, No.12 (2002), 1498-1504. doi:10.1086/344901 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/20175
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil
Other Contributor(s)
Abstract
In an open-label trial carried out on the northwest border of Thailand, 1596 patients with uncomplicated multidrug-resistant falciparum malaria were randomly assigned to receive atovaquone-proguanil, atovaquone-proguanil-artesunate, or artesunate-mefloquine and were followed up for 42 days. All 3 regimens were highly effective and well tolerated. Fever duration and parasite clearance times were significantly shorter among patients who received artesunate (P < .001). Polymerase chain reaction genotyping confirmed that recrudescence occurred in 13 patients who received artesunate-mefloquine (2.4%), 5 who received atovaquone-proguanil-artesunate (0.9%), and 15 who received atovaquone-proguanil (2.8%). Adding artesunate to atovaquone-proguanil reduced the risk of failure 3-fold (95% confidence interval [CI], 1.1-8.2) and subsequent gametocyte carriage 21-fold (95% CI, 14-30). Gastrointestinal complaints in the first 48 h after initiation of treatment were more common among artesunate recipients, but after day 2, dizziness, sleep disturbance, nausea, vomiting, and anorexia were more common among mefloquine recipients (P ≤ .014). Artesunate-atovaquone-proguanil is a highly effective and well-tolerated treatment for multidrug-resistant falciparum malaria.